Matinas BioPharma Holdings (MTNB) Cash from Operations (2013 - 2026)
Matinas BioPharma Holdings (MTNB) reported Cash from Operations of 1601000.0 for Q1 2026, up 20.23% year-over-year from 1331623.29 in Q1 2025, and down 6.1% quarter-over-quarter from 1509000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Cash from Operations (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 14 years of Cash from Operations data on file, last reported at 1601000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 1601000.0, up 20.23% year-over-year; the trailing twelve-month figure through Mar 2026 was 6605000.0 (up 45.52% YoY), and the FY2025 annual result was 7011000.0, up 55.86% from the prior year.
- Cash from Operations slipped to 1601000.0 in Q1 2026 per MTNB's latest filing, from 1509000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 1474000.0 in Q3 2025 and troughed at 5769000.0 in Q1 2024.
- A 5-year average of 3466529.41 and a median of 3510000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations plunged 493.42% in 2022, then surged 65.21% in 2025.
- A 5-year view of Cash from Operations shows it stood at 4299000.0 in 2022, then fell by 6.51% to 4579000.0 in 2023, then advanced by 23.35% to 3510000.0 in 2024, then soared by 57.01% to 1509000.0 in 2025, then slipped by 6.1% to 1601000.0 in 2026.
- Business Quant data shows MTNB's Cash from Operations at 1601000.0 in Q1 2026, 1509000.0 in Q4 2025, and 1474000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - | -1.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.60 Mn |
| Mar 31, 2026 | -1.60 Mn |
| Dec 31, 2025 | -1.51 Mn |
| Dec 31, 2025 | -1.51 Mn |
| Sep 30, 2025 | -1.47 Mn |
| Sep 30, 2025 | -1.47 Mn |
| Jun 30, 2025 | -2.02 Mn |
| Jun 30, 2025 | -2.02 Mn |
| Mar 31, 2025 | -2.01 Mn |
| Mar 31, 2025 | -2.01 Mn |
| Dec 31, 2024 | -3.51 Mn |
| Dec 31, 2024 | -3.51 Mn |
| Sep 30, 2024 | -3.50 Mn |
| Sep 30, 2024 | -3.50 Mn |
| Jun 30, 2024 | -3.11 Mn |
| Jun 30, 2024 | -3.11 Mn |
| Mar 31, 2024 | -5.77 Mn |
| Mar 31, 2024 | -5.77 Mn |
| Dec 31, 2023 | -4.58 Mn |
| Dec 31, 2023 | -4.58 Mn |